1-(2-氨基乙基)-2-甲基-5-硝基咪唑 | 55881-33-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-(2-氨基乙基)-2-甲基-5-硝基咪唑
• 英文名称: 1-(2-aminoethyl)-2-methyl-5-nitro imidazole
• 英文别名: 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethan-1-amine；2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethanamine；(2-methyl-5-nitro-1H-imidazol-1-yl)ethanamine；(amino-2 ethyl)-1 methyl-2 nitro-5 imidazole；2-(2-methyl-5-1H-nitroimidazolyl)ethylamine；1-(2-aminoethyl)-2-methyl-5-nitroimidazole；2-(2-methyl-5-nitroimidazol-1-yl)ethanamine
• CAS: 55881-33-9
• 化学式: C₆H₁₀N₄O₂
• mdl: MFCD07190072
• 分子量: 170.171
• InChiKey: FTZVRGDRIAPBKO-UHFFFAOYSA-N

物化性质

• 沸点：
  376.9±22.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  89.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(2-氨基乙基)-2-甲基-5-硝基咪唑 在 2-硝基咪唑 、 potassium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 38.0h， 生成 N-tert-butyloxycarbonyl-N-<2-(2-methyl-5-nitro-1H-imidazolyl)ethyl>-3-(2-nitro-1H-imidazolyl)propanesulfonamide
  参考文献：
  名称：

  缺氧选择性抗肿瘤药。10.双（硝基咪唑）和相关的双（硝基杂环）：开发在缺氧条件下具有较高代谢活化速率和改善的水溶性的衍生物。

  摘要：

  先前描述的化合物N- [2-（2-甲基-5-硝基咪唑-1H-基）乙基] -4-（2-硝基咪唑-1H-基）丁酰胺的一系列类似物（4），一种新型的低氧细胞已经制备了细胞毒素和放射增敏剂，并对其体外的低氧选择性细胞毒性和低氧细胞放射增敏进行了评估。设计新的衍生物以克服4的低水溶性和在低氧条件下的缓慢杀灭动力学。硝基杂环单元对溶解度有显着影响，其中3-硝基三唑的溶解度是相应的2-硝基咪唑的约6倍。具有一系列中性接头链（多羟基，链烷磺酰胺和双酰胺）的类似物仅显示出略微改善的溶解度，无法完全评估。然而，一系列带有阳离子胺连接基的类似物具有足够的水溶性（最高280 mM）。不能通过直接还原前体酰胺（例如4）来制备胺类似物，并且最方便地通过适当的叠氮化物和醛组分的氮杂-维蒂希缩合合成胺类似物。胺连接的化合物比4具有更高的细胞毒性，对称的双（2-硝基咪唑）衍生物（13和14）的效力最高可达9倍。他们表现出的

  DOI：

  10.1021/jm00011a013
• 作为产物：
  描述：

  N-[2-(2-甲基-5-硝基-1H-咪唑-1-基)乙基]邻苯二甲酰亚胺 在 氢溴酸 作用下， 生成 1-(2-氨基乙基)-2-甲基-5-硝基咪唑
  参考文献：
  名称：

  Synthesis and biological characterisation of novel dithiocarbamate containing 5-nitroimidazole 99mTc-complexes as potential agents for targeting hypoxia

  摘要：

  With the aim to develop new potential Tc-99m-radiopharmaceuticals for imaging hypoxia based on the formation of Tc-nitrido complexes, two novel dithiocarbamate containing metronidazole derivatives (L1 and L2) have been prepared and characterised. The synthesis of L1 and L2 was achieved in excellent yield and high purity. Labelling with Tc-99m was successfully performed using a low ligand concentration (approximately 2-3 mg) and the desired products were obtained with high radiochemical purity (>90%). Lipophilicity, plasma protein binding, and biodistribution in normal- and tumour-bearing-CD1 mice studies were performed to asses the potentiality for nuclear medicine oncology. According to the physicochemical and biological behaviour both in healthy animals and in animals bearing solid tumours complex dtcTc1 could be considered as a starting point for the development of new radiopharmaceuticals for imaging hypoxia. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.10.130

文献信息

• DENDRITIC COMPOUNDS INCLUDING A CHELATING, FLUOROCHROME OR RECOGNITION AGENT, COMPOSITIONS INCLUDING SAME AND USES THEREOF
  申请人：UNIVERSITE DE STRASBOURG

  公开号：US20160221992A1

  公开（公告）日：2016-08-04

  The invention relates to dendritic compounds comprising a chelating, fluorochrome or recognition agent of formula (I), to compositions comprising same, and to uses thereof, wherein in said formula (I): T, L1, D, R, L2, V and n are as defined in the description.

  这项发明涉及包含式(I)的螯合、荧光染料或识别剂的树突化合物，以及包含这些化合物的组合物和它们的用途，其中在所述的式(I)中：T、L1、D、R、L2、V和n如描述中所定义。
• [EN] SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)<br/>[FR] PYRIDONES SUBSTITUES INHIBITEURS DE LA POLY(ADP-RIBOSE) POLYMERASE (PARP)
  申请人：AVENTIS PHARMA INC

  公开号：WO2005097750A1

  公开（公告）日：2005-10-20

  The present invention discloses and claims a series of 2,3,5-substituted pyridone derivatives as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5'-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

  本发明公开并声明了一系列如下定义的2,3,5-取代吡啶酮衍生物。本发明还涉及制备这些化合物的方法。本发明的化合物是多聚腺苷酸二磷酸核糖酶（PARP）的抑制剂，因此在制药剂中特别用于治疗和/或预防各种疾病，包括与中枢神经系统和心血管疾病相关的疾病。
• Epoxysuccinamide derivative or salt thereof
  申请人：Taiho Pharmaceuticals Co., Ltd.

  公开号：US06110967A1

  公开（公告）日：2000-08-29

  The invention relates an epoxysuccinamide derivative represented by a formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom, an alkyl or aminoalkyl group, R.sup.2 represents an aminoalkyl group which May be substituted, an aryl group which may be substituted, a heterocyclic group which may be substituted, an aralkyl group which may be substituted, or an alkyl group substituted by a heterocyclic ring which may be substituted, or R.sup.1 and R.sup.2 may form a nitrogen-containing heterocyclic ring, which may be substituted, together with the adjacent nitrogen atoms, and R.sup.3 and R.sup.4 are the same or different from each other and independently represent a hydrogen atom, or an alkyl or aralkyl group, or a salt thereof, a preparation process thereof, and a medicine comprising such a derivative or salt as an active ingredient. This compound has a specific inhibitory activity for cathepsin L and family enzymes thereof, and is useful as an agent for preventing and treating metabolic osteopathy such as osteoporosis and hypercalcemia.

  该发明涉及一种由以下式（I）表示的环氧琥珀酰胺衍生物：##STR1##其中R.sup.1代表氢原子、烷基或氨基烷基基团，R.sup.2代表可能被取代的氨基烷基基团、可能被取代的芳基、可能被取代的杂环基、可能被取代的芳基烷基基团，或者可能被取代的杂环环取代的烷基基团，或者R.sup.1和R.sup.2可以形成含氮杂环环，该环可能被取代，与相邻的氮原子一起，R.sup.3和R.sup.4彼此相同或不同且独立地表示氢原子，或者烷基或芳基烷基基团，或其盐，其制备方法以及包含该衍生物或盐作为活性成分的药物。该化合物具有对半胱氨酸蛋白酶L及其家族酶的特异性抑制活性，并且可用作预防和治疗代谢性骨病如骨质疏松症和高钙血症的药物。
• Amino acid-linked porphyrin-nitroimidazole antibiotics targeting Porphyromonas gingivalis
  作者：Simon A. Dingsdag、Benjamin C-M. Yap、Neil Hunter、Maxwell J. Crossley

  DOI：10.1039/c4ob01841a

  日期：——

  Amino acid-linked porphyrin-nitroimidazole adducts, as potent as metronidazole, are highly selective forPorphyromonas gingivalis.

  氨基酸连接的卟啉-硝基咪唑加合物与甲硝唑一样有效，对牙龈拟杆菌具有高度选择性。
• Crystal Habit Modification of Metronidazole by Supramolecular Gels with Complementary Functionality
  作者：Sreejith Sudhakaran Jayabhavan、Jonathan W. Steed、Krishna K. Damodaran

  DOI：10.1021/acs.cgd.1c00659

  日期：2021.9.1

  A series of bis(urea) compounds with complementary functional groups similar to the pharmaceutical drug metronidazole and a structural isomer isometronidazole have been synthesized. The gelation properties of these compounds were studied in various solvent/solvent mixtures. The mechanical strength of the isomeric gelators was compared using rheology, and the morphologies of the xerogels were analyzed by scanning electron microscopy. These gels were used as media for metronidazole crystallization resulting in a marked habit modification of the metronidazole crystals in the drug-mimicking gels. However, crystallization in the nonmimetic isomeric gel resulted in morphologies similar to the solution state. These results indicate that the drug-mimetic gels interact with the surface of the drug crystal giving rise to new morphologies.

  合成了一系列具有与药物甲硝唑相似的互补功能团的双（脲）化合物及其结构异构体异甲硝唑。研究了这些化合物在不同溶剂/溶剂混合物中的成胶特性。使用流变学比较了异构体凝胶剂的机械强度，并通过扫描电子显微镜分析了干凝胶的形态。这些凝胶被用作甲硝唑结晶的介质，导致在类药物凝胶中甲硝唑晶体的形态发生显著变化。然而，在非类药物异构体凝胶中的结晶结果显示出与溶液状态类似的形态。这些结果表明，类药物凝胶与药物晶体的表面相互作用，从而产生了新的形态。